{"id":"eptifibatide-facilitated-pci","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1174","moleculeType":"Protein","molecularWeight":"831.98"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eptifibatide is a cyclic heptapeptide that reversibly binds to the glycoprotein IIb/IIIa receptor on platelet surfaces, inhibiting the final common pathway of platelet aggregation. By blocking fibrinogen and von Willebrand factor from cross-linking platelets, it reduces thrombotic complications during PCI procedures. The drug is administered intravenously as a bolus followed by infusion during the intervention.","oneSentence":"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors during percutaneous coronary intervention.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:19.440Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome undergoing percutaneous coronary intervention (PCI)"},{"name":"Prevention of ischemic complications during PCI in high-risk patients"}]},"trialDetails":[{"nctId":"NCT00251823","phase":"PHASE3","title":"Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2005-07","conditions":"Myocardial Infarction","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eptifibatide facilitated PCI","genericName":"Eptifibatide facilitated PCI","companyName":"Ottawa Heart Institute Research Corporation","companyId":"ottawa-heart-institute-research-corporation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eptifibatide is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to platelet receptors during percutaneous coronary intervention. Used for Acute coronary syndrome undergoing percutaneous coronary intervention (PCI), Prevention of ischemic complications during PCI in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}